Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

1. Plus Sutures for preventing surgical site infection

Plus Sutures for preventing surgical site infection Plus Sutures for preventing surgical site infection Medtech innovation briefing Published: 4 February 2020 www.nice.org.uk/guidance/mib204 pathways Summary Summary The technology technology described in this briefing is Plus Sutures. It is for wound closure in adults and children after surgical procedures. The innovative aspect innovative aspect is that the sutures contain the antimicrobial substance triclosan. The intended place in therapy (...) place in therapy would be as an alternative to standard care for people who need wound closure after a surgical procedure. The main points from the evidence main points from the evidence summarised in this briefing are from 7 studies, including 3 meta-analyses, 1 systematic review and 3 randomised controlled trials including adults and children in a secondary care setting. Most studies found Plus Sutures more effective than standard care sutures in reducing surgical site infections. Key

2020 National Institute for Health and Clinical Excellence - Advice

2. Infection prevention and control for novel coronavirus (COVID-19): interim guidance for acute healthcare settings

within the Healthcare Setting The organization's Occupational Health Service professional(s), attending physicians (including infectious diseases specialists), and infection control professional(s) should work collaboratively with public health authorities to manage exposed HCWs. Bibliography Public Health Agency of Canada. (2012). https://www.canada.ca/en/public-health/services/infectious-diseases/nosocomial-occupational-infections/hand-hygiene-practices-healthcare-settings.html Public Health Agency (...) of Canada. (2018). https://www.canada.ca/en/public-health/services/publications/diseases-conditions/infection-prevention-control-guidance-middle-east-respiratory-syndrome-coronavirus-mers-cov-acute-care-settings.html Public Health Agency of Canada. (2013). https://www.canada.ca/en/public-health/services/infectious-diseases/nosocomial-occupational-infections/routine-practices-additional-precautions-preventing-transmission-infection-healthcare-settings.html Public Health England. (Updated 15 January 2020

2020 CPG Infobase

3. Clinical Practice Guideline on the Diagnosis and Prevention of Periprosthetic Joint Infections

Clinical Practice Guideline on the Diagnosis and Prevention of Periprosthetic Joint Infections 1 View the background material via the PJI CPG eAppendix 1 View data summaries via the PJI CPG eAppendix 2 DIAGNOSIS AND PREVENTION OF PERIPROSTHETIC JOINT INFECTIONS CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors March 11, 2019 Endorsed by: Please cite this guideline as: American Academy of Orthopaedic Surgeons. Diagnosis and Prevention (...) of Periprosthetic Joint Infections Clinical Practice Guideline. https://www.aaos.org/pjiguideline. Published March 11, 2019.2 View the background material via the PJI CPG eAppendix 1 View data summaries via the PJI CPG eAppendix 2 Disclaimer This clinical practice guideline was developed by a physician volunteer clinical practice guideline development group based on a formal systematic review of the available scientific evidence and accepted approaches to care. This clinical practice guideline is not intended

2020 American Academy of Orthopaedic Surgeons

4. Clostridioides difficile Infection in Adults and Children

Clostridioides difficile Infection in Adults and Children Quality Department Guidelines for Clinical Care 1 UMHS C. difficile Infection in Adults and Children 12/2019 Clostridioides difficile Infection Guideline Team Team Leads Tejal N Gandhi MD Infectious Diseases Krishna Rao, MD Infectious Diseases Team Members Gregory Eschenauer, PharmD Pharmacy John Y Kao, MD Gastroenterology Lena M Napolitano, MD Surgery F Jacob Seagull, PhD Leaning Heath Sciences David M Somand, MD Emergency Medicine (...) Alison C Tribble, MD Pediatric Infectious Diseases Amanda M Valyko, MPH, CIC Infection Control Michael E Watson Jr, MD, PhD Pediatric Infectious Diseases Consultants: Meghan A. Arnold, MD Pediatric Surgery Laraine Lynn Washer, MD Infection Diseases Initial Release: December 2016 Most Recent Major Update December 2019 Inpatient Clinical Guidelines Oversight Megan R Mack, MD David H Wesorick, MD F Jacob Seagull, PhD Literature search service Taubman Health Sciences Library For more information: 734

2020 University of Michigan Health System

5. Leg ulcer infection: antimicrobial prescribing

Leg ulcer infection: antimicrobial prescribing Leg ulcer infection: antimicrobial prescribing NICE guideline Published: 11 February 2020 www.nice.org.uk/guidance/ng152 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Leg ulcer infection: antimicrobial prescribing (NG152) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Managing leg ulcer

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

6. Is IV iron safe to give in patients with active infection?

Is IV iron safe to give in patients with active infection? Chiefs’ Inquiry Corner – 1/27/20 – Clinical Correlations Search Chiefs’ Inquiry Corner – 1/27/20 January 27, 2020 2 min read The iron-infection hypothesis postulates that because bacteria need iron to survive and replicate, our bodies have evolved to respond to infections by sequestering iron intracellularly away from the extracellular bacteria. Although the most recent, large meta-analysis suggests routine use of IV iron (...) was not associated with an increased risk of infections, is there any data on the safety of giving IV iron to patients who are actively infected? Sadly, there is no good data for humans (only animal studies). So, as always, weigh the risks and benefits each time. References: It is an established phenomenon that patients with well-controlled HIV can see a tremendous drop in their CD4 count during acute illness. This effect can also be seen in critically ill patients even without HIV. This drop is transient

2020 Clinical Correlations

7. Infection prevention and control

Infection prevention and control Guidelines Infection prevention and control 2020 January 20202 Association of Anaesthetists | Infection prevention and control 2020 Infection prevention and control 2020 Membership of the working party C.R. Bailey, 1 B. Greatorex, 2 Y. Hyde, 3 R. Koerner, 4 N. McGuire, 5 T. Meek 6 and S. Radhakrishna 7 1 Consultant, Department of Anaesthetics, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; Chair of Working Party, Association of Anaesthetists 2 Specialist (...) Trainee, Department of Anaesthetics, John Radcliffe Hospital, Oxford, UK; Association of Anaesthetists Trainee Committee 3 Senior Infection Prevention and Control Nurse, Cardiff and Vale University Health Board, Cardiff, UK 4 Consultant, Department of Microbiology, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK 5 Clinical Director of Medical Devices, Medicines and Healthcare products Regulatory Agency 6 Consultant, Department of Anaesthetics, South Tees Hospitals NHS Foundation Trust

2020 Association of Anaesthetists of GB and Ireland

8. Gastrointestinal infections: guidance for public health management

Gastrointestinal infections: guidance for public health management Gastrointestinal infections: guidance for public health management - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search The UK has left the EU Guidance Gastrointestinal infections: guidance for public health management (...) Guidance to help professionals in public health and environmental health departments to minimise the risk of transmission of gastrointestinal infections. Published 31 January 2020 From: Documents Ref: PHE publications gateway number: GW-1020 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This guidance

2020 Public Health England

9. 2019 EHRA International Consensus Document on How to Prevent, Diagnose, and Treat Cardiac Implantable Electronic Device Infections

2019 EHRA International Consensus Document on How to Prevent, Diagnose, and Treat Cardiac Implantable Electronic Device Infections 2019 EHRA International Consensus Document on How to Prevent, Diagnose, and Treat Cardiac Implantable Electronic Device Infections | Heart Rhythm Society Utility Menu Main navigation Search Main Menu Breadcrumb Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are life-saving treatments for a number of cardiac conditions (...) . Device-related infection is, however, one of the most serious complications of cardiac implantable electronic device (CIED) therapy associated with significant morbidity, mortality, and financial health care burden. Although many preventive strategies such as administration of intravenous antibiotic therapy before implantation are well recognized, uncertainties still exist about other regimens. Questions still remain such as the use of CIED alternatives expected to be less prone to infections and how

2020 Heart Rhythm Society

10. European surveillance of Clostridioides (Clostridium) difficile infections - surveillance protocol version 2.4

-associated infections ATC Anatomical Therapeutic Chemical classification system CA CDI Community-associated Clostridioides difficile infection CDI Clostridioides difficile infection, previously also referred to as Clostridium difficile infection and C. difficile associated diarrhoea (CDAD) DDD Defined daily dose ECDIS-Net European Clostridium difficile Infection Network project ESCMID European Society of Clinical Microbiology and Infectious Diseases ESGCD ESCMID Study Group for Clostridioides difficile (...) further information about options to participate should contact their National Focal Point for Healthcare- Associated Infections in their country 3 . 1 Consortium composed of Leiden University Medical Center, the Netherlands (E.J. Kuijper, coordination), University of Leeds and the Health Protection Agency, England, United Kingdom (M. Wilcox), University Hospital of Wales, Cardiff, United Kingdom (V. Hall), Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands (D. Notermans), Charité

2020 European Centre for Disease Prevention and Control - Technical Guidance

11. Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group

to identify factors predicting severe infections (SI) in SNV. Methods: Data from five randomized controlled trials (RCTs) enrolling 733 patients were pooled. The primary end point was the occurrence of SI, defined by the need of a hospitalization and/or intravenous anti-infectious treatment and/or leading to death. Results: After a median follow-up of 5.2 (interquartile range 3-9.7) years, 148 (20.2%) patients experienced 189 SI, and 98 (66.2%) presented their first SI within the first 2 years. Median (...) Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group Predictive Factors of Severe Infections in Patients With Systemic Necrotizing Vasculitides: Data From 733 Patients Enrolled in Five Randomized Controlled Trials of the French Vasculitis Study Group - PubMed This site needs JavaScript to work properly. Please enable it to take advantage

2020 EvidenceUpdates

12. Diabetic Foot Infections

Diabetic Foot Infections Quality Department Guidelines for Clinical Care Inpatient 1 UMHS Diabetic Foot Infection 10/2019 Diabetic Foot Infection Guideline Team Team Leaders John P. Mills, MD Infectious Disease Payal Patel, MD Infectious Disease Team Members Stephanie Burdick, MD Internal Medicine Christina DeGeorge, PA-C Endocrinology Katherine A. Gallagher, MD Vascular Surgery Crystal M. Holmes, DPM Podiatry Jon A. Jacobson, MD Radiology Jerod L. Nagel, PharmD Pharmacy F. Jacob Seagull, PhD (...) diabetic foot infection is summarized in Figure 1. History should focus on acuity and severity of the infection and physical exam should assess the skin, vascular, neurological and musculoskeletal systems. [I-C] Grading of severity can be done using the Infectious Diseases Society of America classification scheme (Table 1). [I-C] Ankle Brachial Index and Toe Brachial Index (ABI/TBI) measurements should be taken to evaluate for underlying peripheral vascular disease. Perform an initial x-ray to evaluate

2020 University of Michigan Health System

13. Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA) - Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

gastrointestinal symptoms, such as nausea, vomiting, or diarrhoea. Acute kidney injury has also been reported in up to half of critically ill patients. A case of MERS-CoV is assumed to be infectious only upon symptom onset and not prior to that. Shedding of viral RNA in respiratory secretions appears to be dependent on the severity of illness and has been documented up to 28 days following symptom onset [13,14]. The virus can also be isolated from infected, but non-symptomatic or mildly symptomatic individuals (...) -coronavirus-(mers-cov) 4. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious diseases. 2013 Sep;13(9):752-61. 5. Senga M, Arabi YM, Fowler RA. Clinical spectrum of the Middle East respiratory syndrome coronavirus (MERS- CoV). Journal of infection and public health. 2017 Mar - Apr;10(2

2020 European Centre for Disease Prevention and Control - Technical Guidance

14. COVID-19: infection prevention and control

COVID-19: infection prevention and control Wuhan novel coronavirus: infection prevention and control - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Wuhan novel coronavirus: infection prevention and control Guidance on infection prevention and control for Wuhan novel (...) coronavirus. Published 10 January 2020 Last updated 15 January 2020 — From: Documents HTML Details This guidance outlines infection control for healthcare providers assessing possible cases of WN-CoV. It should be used in conjunction with local policies. In the absence of effective drugs or a vaccine, control of this virus relies on the prompt identification, appropriate risk assessment, management and isolation of possible and confirmed cases, and the investigation and follow up of close contacts

2020 Public Health England

15. Infants born to hepatitis B-infected mothers: immunoglobulin policy

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

2020 Public Health England

16. Cefiderocol (Fetroja) - urinary tract infections

Cefiderocol (Fetroja) - urinary tract infections Drug Approval Package: FETROJA (cefiderocol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: FETROJA (cefiderocol) Company: Shionogi, Inc. Application Number: 209445Orig1s000 Approval Date: 11/14/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

17. The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP

limited to English articles published since 2015. Reference lists of identified articles were also searched. The search yielded 1,343 references from which 28 were included. Reference list Newman DR, Rahman MM, Brantley A, Peterman TA. Rates of new human immunodeficiency virus (HIV) diagnoses after reported sexually transmitted infection in women in Louisiana, 2000–2015: Implications for HIV prevention. Clinical Infectious Diseases. 2019. Peterman TA, Newman DR, Maddox L, Schmitt K, Shiver S. Risk (...) The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually

2020 Ontario HIV Treatment Network

18. Delafloxacin (Quofenix) - bacterial infections of the skin and underlying tissues

Delafloxacin (Quofenix) - bacterial infections of the skin and underlying tissues Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/572803/2019 EMEA/H/C/004860 Quofenix (...) (delafloxacin) An overview of Quofenix and why it is authorised in the EU What is Quofenix and what is it used for? Quofenix is an antibiotic used in adults to treat bacterial infections of the skin and underlying tissues (acute bacterial skin and skin structure infections) when other medicines are not suitable. It contains the active substance delafloxacin. How is Quofenix used? Quofenix is available as a powder to be made into a solution for infusion (300 mg) and as tablets (450 mg). Quofenix is given

2020 European Medicines Agency - EPARs

19. Prognostic accuracy of qSOFA in predicting 28-day mortality among infected patients in an emergency department: a prospective validation study Full Text available with Trip Pro

; diagnosis; emergency department; infectious diseases. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. Conflict of interest statement Competing interests: None declared. Similar articles J Jiang et al. Scand J Trauma Resusc Emerg Med 26 (1), 56. 2018. PMID 29996880. - Review A qSOFA score ≥ 2 and SIRS score ≥ 2 are strongly associated with mortality in ED patients with infections. However, it is also clear that qSOFA and SIRS have limitations (...) Prognostic accuracy of qSOFA in predicting 28-day mortality among infected patients in an emergency department: a prospective validation study Prognostic Accuracy of qSOFA in Predicting 28-day Mortality Among Infected Patients in an Emergency Department: A Prospective Validation Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several

2020 EvidenceUpdates

20. Analysis of emergency department prediction tools in evaluating febrile young infants at risk for serious infections

Analysis of emergency department prediction tools in evaluating febrile young infants at risk for serious infections Analysis of Emergency Department Prediction Tools in Evaluating Febrile Young Infants at Risk for Serious Infections - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable (...) your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Emerg Med J Actions , 36 (12), 729-735 Dec 2019 Analysis of Emergency Department Prediction Tools in Evaluating Febrile Young Infants at Risk for Serious Infections , , , , Affiliations Expand Affiliations 1 Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore, Singapore. 2 Faculty

2020 EvidenceUpdates